Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B

Authors :: Howard Levy
Frank Del Greco
Martin Lee
Johnny Mahlangu
Source :: Haemophilia : the official journal of the World Federation of Hemophilia, vol 27, iss 4, Haemophilia
Publication Year :: 2021
Publisher :: eScholarship, University of California, 2021.
Abstract: AimPhase 2b study to assess efficacy, safety, thrombogenicity, immunogenicity and tolerability with 28days of daily dosing of subcutaneous (SQ) dalcinonacog alfa as prophylaxis for haemophilia B (HB).MethodsAdult males with a confirmed diagnosis of congenital HB (factor IX [FIX] activity

Database :: OpenAIRE
Journal :: Haemophilia : the official journal of the World Federation of Hemophilia, vol 27, iss 4, Haemophilia
Accession number :: edsair.doi.dedup.....541b33ba0a83fb581ee23a7322f35a6a

Tools